• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

    2/9/22 3:43:31 PM ET
    $CODX
    Medical/Dental Instruments
    Health Care
    Get the next $CODX alert in real time by email
    SC 13G/A 1 tv0618-codiagnosticsinc.htm SCHEDULE 13G/A codiagnosticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Co-Diagnostics Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  189763105

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  189763105

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    5,163

    7.  SOLE DISPOSITIVE POWER

    1,781,167

    8.  SHARED DISPOSITIVE POWER

    13,890

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,795,057

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.30%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Co-Diagnostics Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2401 South Foothill Drive, Suite D
    Salt Lake City, UT 84109

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    189763105

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $CODX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CODX

    DatePrice TargetRatingAnalyst
    8/12/2022$5.00Buy → Neutral
    Sidoti
    12/29/2021$14.00Buy
    Sidoti
    11/12/2021$16.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CODX
    Financials

    Live finance-specific insights

    See more
    • Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

      SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:  ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025    ●Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter    ●Operating loss of $8.6 million compared to operating loss of $10.3 million in Q

      5/8/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagn

      4/29/25 7:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results

      SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue totaled $3.1 million while product revenue totaled $0.8 millionOperating expenses of $43.0 million decreased by 5

      3/27/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Egan Dwight H returned $12,407 worth of shares to the company (51,697 units at $0.24) and was granted 163,334 shares, increasing direct ownership by 21% to 634,494 units (SEC Form 4)

      4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

      5/27/25 4:09:40 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Brown Brian Lee was granted 134,166 shares and returned $11,559 worth of shares to the company (48,161 units at $0.24), increasing direct ownership by 20% to 505,911 units (SEC Form 4)

      4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

      5/27/25 4:09:30 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • President Abbott Richard David was granted 20,000 shares and returned $1,723 worth of shares to the company (7,180 units at $0.24), increasing direct ownership by 92% to 26,735 units (SEC Form 4)

      4 - Co-Diagnostics, Inc. (0001692415) (Issuer)

      5/27/25 4:09:19 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

      SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

      2/13/24 5:02:32 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Co-Diagnostics Inc. (Amendment)

      SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

      2/9/22 3:43:31 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Co-Diagnostics, Inc. (Amendment)

      SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)

      7/12/21 8:29:19 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    SEC Filings

    See more
    • Co-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/29/25 4:30:38 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Co-Diagnostics Inc.

      10-Q - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/8/25 4:10:37 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Co-Diagnostics, Inc. (0001692415) (Filer)

      5/8/25 4:05:13 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Co-Diagnostics downgraded by Sidoti with a new price target

      Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00

      8/12/22 9:07:51 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Sidoti initiated coverage on Co-Diagnostics with a new price target

      Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00

      12/29/21 8:45:34 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Co-Diagnostics with a new price target

      HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously

      11/12/21 6:13:11 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care

    $CODX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CODX
    Leadership Updates

    Live Leadership Updates

    See more
    • Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

      Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital ("DBC") Inaugural Global Conference on May 14, 2025 in New York City. The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions to the Company's value proposition and to the upcoming Co-Dx PCR* testing platform. More information about the conferen

      5/14/25 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

      SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results:  ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025    ●Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter    ●Operating loss of $8.6 million compared to operating loss of $10.3 million in Q

      5/8/25 4:01:00 PM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations. The conference call and webcast will be available via: Webcast: ir.codiagn

      4/29/25 7:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions

      SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com

      4/4/24 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer

      SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i

      8/29/23 9:30:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care
    • Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

      SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on inf

      11/1/22 9:32:00 AM ET
      $CODX
      Medical/Dental Instruments
      Health Care